Analyst Viewpoint
Surge in R&D investment in the pharmaceutical sector is a key factor that is fostering drug discovery informatics market development. Data-driven software and techniques offer assistance to researchers by optimizing the drug design and development process. They help in pre-clinical research, drug target identification, and prediction of drug resistance and side effects. Advancements in data science such as sophisticated data analytics and machine learning tools are also propelling drug discovery informatics industry size.
Critical research of conventional methods of drug development makes up for the majority of the R&D expenditure of big pharmaceutical firms. Prominent players in the global drug discovery informatics market are investing significantly in AI-driven drug discovery innovations. They are also using novel data-driven tools for digital transformation of the healthcare sector.
Drug discovery informatics entails the adoption of information technology to assist researchers in drug discovery and creation process. The process requires the usage of computational methods and tools such as Artificial Intelligence and advanced software to analyze large sets of biochemical data in order to identify possible drug candidates.
Drug discovery is a time and resource-draining initiative that involves isolating and fostering a compound that shows signs of treating an infection in a meaningful way A developed drug has to further meet strict health and safety regulations to be deemed safe and adequate for administration.
Individual bioinformatics tools and databases are constantly being updated to allow for the optimization of the drug discovery process, as vast sets of biological, chemical, and toxicological data can be analyzed to assist in novel drug development.
Pharmaceutical companies rely on data-driven informatics software to assist them in pre-clinical research, lead identification, and compound screening. They use this data to identify patterns, test theories, and understand the efficacy of treatments. Companies are investing significantly in R&D cycle of new drugs.
According to a report by Evaluate Pharma, the top 11 pharma firms globally invested more than US$ 104.0 Bn on R&D in 2022, accounting for 42% of total pharma research spending worldwide.
Surge in spending on R&D with long-term strategic aims helps build a foundation for the integration of public data with internal datasets and frameworks. It also allows for machine learning and artificial intelligence to train on well-managed datasets and help in standardization and centralization of sensitive information for better results.
As per the Information Technology & Innovation Foundation of the U.S., advancements in data science are likely to enable pharmaceutical companies to save about US$ 5.4 Bn in R&D costs each year. These developments are fostering the drug discovery informatics market value.
Integration of innovative data analytics, machine learning algorithms, and artificial intelligence (AI) substantially improves the drug discovery process. These tools enhance efficiency, identify patterns, and assist researchers in making data-driven decisions to reduce strain on both time and capital.
As per Stanford University’s 2021 Artificial Intelligence Index, the capital invested in AI-powered drug discovery stood at US$ 13.8 Bn in 2020.
Big data and AI contribute to the exploration of drug therapeutics from several perspectives such as genomics and pathways. They also facilitate molecular simulation and predictive modeling of active drug action, thus improving the chances of cataloging side effects and potential obstacles in development.
The inclusion of Artificial Intelligence and data analytics in drug manufacturing opens the pathway for personalized medicine and accelerates the time it takes for the said drugs to reach the market.
According to a recent drug discovery informatics market analysis, North America accounted for the largest share of the global landscape in 2022. Presence of a well-developed healthcare sector, rise in awareness about drug testing, and R&D of progressive drug discovery solutions are augmenting the market dynamics of the region.
As per the American Journal of Health-System Pharmacy, pharmaceutical expenditure in the U.S. reached a record US$ 535.3 Bn in 2020.
According to the latest drug discovery informatics market regional insights, Asia Pacific is a lucrative region for drug discovery informatics, led by the expansion of pharmacology and biotechnology industries and rise in awareness about indigenous drug development in various countries in the region.
As per Invest India, 62% of the global vaccine demand is met by India, making it the largest vaccine provider.
According to recent drug discovery informatics market trends, prominent manufacturers are investing substantially in the development of pharmaceutical informatics and computational drug discovery technologies.
They are carrying out advancements in conventional drug testing to resolve critical issues for both patients and healthcare workers.
Charles River Laboratories International, Inc., Thermo Fisher Scientific, PerkinElmer Inc., Biogen Inc., Boehringer Ingelheim GmbH, Insilico Medicine, Inc., International Business Machines Corporation, Schrödinger, LLC, Curia Global, Inc., Certara, USA are key firms that account for significant drug discovery informatics market share.
The drug discovery informatics market report highlights the leading companies in the global landscape in terms of parameters such as company overview, business strategies, product portfolio, financial overview, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 2.7 Bn |
| Market Forecast Value in 2031 | US$ 6.8 Bn |
| Growth Rate (CAGR) | 10.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Regions Covered |
|
| Countries Covered |
|
| Market Segmentation |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 2.7 Bn in 2022
It is projected to advance at a CAGR of 10.9% from 2023 to 2031
Surge in R&D investment in the pharmaceutical sector and advancements in data science
The sequencing and target data analysis function segment constituted the largest share in 2022
North America was the leading region in 2022
Charles River Laboratories International, Inc., Thermo Fisher Scientific, PerkinElmer Inc., Biogen Inc., Boehringer Ingelheim GmbH, Insilico Medicine, Inc., International Business Machines Corporation, Schrödinger, LLC, Curia Global, Inc., Certara, USA
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug Discovery Informatics Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug Discovery Informatics Market Analysis and Forecast, 2023-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug Discovery Informatics Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Discovery Informatics
6.3.2. Development Informatics
6.4. Market Attractiveness, by Product
7. Global Drug Discovery Informatics Market Analysis and Forecast, by Mode
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Mode, 2017–2031
7.3.1. In-house Informatics
7.3.2. Outsourced Informatics
7.4. Market Attractiveness, by Mode
8. Global Drug Discovery Informatics Market Analysis and Forecast, by Function
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Function, 2017–2031
8.3.1. Sequencing and Target Data Analysis
8.3.2. Docking
8.3.3. Lead Generation Informatics
8.3.4. Identification and Validation Informatics
8.3.5. Molecular Modeling
8.3.6. Others
8.4. Market Attractiveness, by Function
9. Global Drug Discovery Informatics Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Pharmaceutical and Biotechnology Companies
9.3.2. Contract Research Organizations
9.3.3. Others
9.4. Market Attractiveness, by End-user
10. Global Drug Discovery Informatics Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Drug Discovery Informatics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Discovery Informatics
11.2.2. Development Informatics
11.3. Market Attractiveness, by Product
11.4. Market Value Forecast, by Mode, 2017–2031
11.4.1. In-house Informatics
11.4.2. Outsourced Informatics
11.5. Market Attractiveness, by Mode
11.6. Market Value Forecast, by Function, 2017–2031
11.6.1. Sequencing and Target Data Analysis
11.6.2. Docking
11.6.3. Lead Generation Informatics
11.6.4. Identification and Validation Informatics
11.6.5. Molecular Modeling
11.6.6. Others
11.7. Market Attractiveness, by Function
11.8. Market Value Forecast, by End-user
11.8.1. Pharmaceutical and Biotechnology Companies
11.8.2. Contract Research Organizations
11.8.3. Others
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Product
11.11.2. By Mode
11.11.3. By Function
11.11.4. By End-user
11.11.5. By Country
12. Europe Drug Discovery Informatics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Discovery Informatics
12.2.2. Development Informatics
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Mode, 2017–2031
12.4.1. In-house Informatics
12.4.2. Outsourced Informatics
12.5. Market Attractiveness, by Mode
12.6. Market Value Forecast, by Function, 2017–2031
12.6.1. Sequencing and Target Data Analysis
12.6.2. Docking
12.6.3. Lead Generation Informatics
12.6.4. Identification and Validation Informatics
12.6.5. Molecular Modeling
12.6.6. Others
12.7. Market Attractiveness, by Function
12.8. Market Value Forecast, by End-user, 2017–2031
12.8.1. Pharmaceutical and Biotechnology Companies
12.8.2. Contract Research Organizations
12.8.3. Others
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Product
12.11.2. By Mode
12.11.3. By Function
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Drug Discovery Informatics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Discovery Informatics
13.2.2. Development Informatics
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Mode, 2017–2031
13.4.1. In-house Informatics
13.4.2. Outsourced Informatics
13.5. Market Attractiveness, by Mode
13.6. Market Value Forecast, by Function, 2017–2031
13.6.1. Sequencing and Target Data Analysis
13.6.2. Docking
13.6.3. Lead Generation Informatics
13.6.4. Identification and Validation Informatics
13.6.5. Molecular Modeling
13.6.6. Others
13.7. Market Attractiveness, by Function
13.8. Market Value Forecast, by End-user, 2017–2031
13.8.1. Pharmaceutical and Biotechnology Companies
13.8.2. Contract Research Organizations
13.8.3. Others
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Product
13.11.2. By Mode
13.11.3. By Function
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Drug Discovery Informatics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Discovery Informatics
14.2.2. Development Informatics
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Mode, 2017–2031
14.4.1. In-house Informatics
14.4.2. Outsourced Informatics
14.5. Market Attractiveness, by Mode
14.6. Market Value Forecast, by Function, 2017–2031
14.6.1. Sequencing and Target Data Analysis
14.6.2. Docking
14.6.3. Lead Generation Informatics
14.6.4. Identification and Validation Informatics
14.6.5. Molecular Modeling
14.6.6. Others
14.7. Market Attractiveness, by Function
14.8. Market Value Forecast, by End-user, 2017–2031
14.8.1. Pharmaceutical and Biotechnology Companies
14.8.2. Contract Research Organizations
14.8.3. Others
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Product
14.11.2. By Mode
14.11.3. By Function
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Drug Discovery Informatics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Discovery Informatics
15.2.2. Development Informatics
15.3. Market Attractiveness, by Product
15.4. Market Value Forecast, by Mode, 2017–2031
15.4.1. In-house Informatics
15.4.2. Outsourced Informatics
15.5. Market Attractiveness, by Mode
15.6. Market Value Forecast, by Function, 2017–2031
15.6.1. Sequencing and Target Data Analysis
15.6.2. Docking
15.6.3. Lead Generation Informatics
15.6.4. Identification and Validation Informatics
15.6.5. Molecular Modeling
15.6.6. Others
15.7. Market Attractiveness, by Function
15.8. Market Value Forecast, by End-user, 2017–2031
15.8.1. Pharmaceutical and Biotechnology Companies
15.8.2. Contract Research Organizations
15.8.3. Others
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Product
15.11.2. By Mode
15.11.3. By Function
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Charles River Laboratories International, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Thermo Fisher Scientific
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. PerkinElmer Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Biogen Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Boehringer Ingelheim GmbH
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Insilico Medicine, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. International Business Machines Corporation
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Schrödinger, LLC
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Curia Global, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Certara, USA
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Mode, 2017–2031
Table 03: Global Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Function, 2017–2031
Table 04: Global Drug Discovery Informatics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 05: Global Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 08: North America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Mode, 2017–2031
Table 09: North America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Function, 2017–2031
Table 10: North America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 11: Europe Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 13: Europe Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Mode, 2017–2031
Table 14: Europe Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Function, 2017–2031
Table 15: Europe Drug Discovery Informatics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 16: Asia Pacific Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 18: Asia Pacific Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Mode, 2017–2031
Table 19: Asia Pacific Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Function, 2017–2031
Table 20: Asia Pacific Drug Discovery Informatics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Latin America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 23: Latin America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Mode, 2017–2031
Table 24: Latin America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Function, 2017–2031
Table 25: Latin America Drug Discovery Informatics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 26: Middle East & Africa Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 28: Middle East & Africa Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Mode, 2017–2031
Table 29: Middle East & Africa Drug Discovery Informatics Market Size (US$ Mn) Forecast, by Function, 2017–2031
Table 30: Middle East & Africa Drug Discovery Informatics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Drug Discovery Informatics Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Drug Discovery Informatics Market Revenue (US$ Mn), by Product, 2022
Figure 03: Global Drug Discovery Informatics Market Value Share, by Product, 2022
Figure 04: Global Drug Discovery Informatics Market Revenue (US$ Mn), by Mode, 2022
Figure 05: Global Drug Discovery Informatics Market Value Share, by Mode, 2022
Figure 06: Global Drug Discovery Informatics Market Revenue (US$ Mn), by Function, 2022
Figure 07: Global Drug Discovery Informatics Market Value Share, by Function, 2022
Figure 08: Global Drug Discovery Informatics Market Value Share, by End-user, 2022
Figure 09: Global Drug Discovery Informatics Market Value Share, by End-user, 2022
Figure 10: Global Drug Discovery Informatics Market Value Share, by Region, 2022
Figure 11: Global Drug Discovery Informatics Market Value (US$ Mn) Forecast, 2017–2031
Figure 12: Global Drug Discovery Informatics Market Value Share Analysis, by Product, 2022 and 2031
Figure 13: Global Drug Discovery Informatics Market Attractiveness Analysis, by Product, 2023-2031
Figure 14: Global Drug Discovery Informatics Market Value Share Analysis, by Mode, 2022 and 2031
Figure 15: Global Drug Discovery Informatics Market Attractiveness Analysis, by Mode, 2023-2031
Figure 16: Global Drug Discovery Informatics Market Value Share Analysis, by Function, 2022 and 2031
Figure 17: Global Drug Discovery Informatics Market Attractiveness Analysis, by Function, 2023-2031
Figure 18: Global Drug Discovery Informatics Market Revenue (US$ Mn), by End-user, 2022
Figure 19: Global Drug Discovery Informatics Market Value Share, by End-user, 2022
Figure 20: Global Drug Discovery Informatics Market Value Share Analysis, by Region, 2022 and 2031
Figure 21: Global Drug Discovery Informatics Market Attractiveness Analysis, by Region, 2023-2031
Figure 22: North America Drug Discovery Informatics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 23: North America Drug Discovery Informatics Market Attractiveness Analysis, by Country, 2023–2031
Figure 24: North America Drug Discovery Informatics Market Value Share Analysis, by Country, 2022 and 2031
Figure 25: North America Drug Discovery Informatics Market Value Share Analysis, by Product, 2022 and 2031
Figure 26: North America Drug Discovery Informatics Market Value Share Analysis, by Mode, 2022 and 2031
Figure 27: North America Drug Discovery Informatics Market Value Share Analysis, by Function, 2022 and 2031
Figure 28: North America Drug Discovery Informatics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 29: North America Drug Discovery Informatics Market Attractiveness Analysis, by Product, 2023–2031
Figure 30: North America Drug Discovery Informatics Market Attractiveness Analysis, by Mode, 2023–2031
Figure 31: North America Drug Discovery Informatics Market Attractiveness Analysis, by Function, 2023–2031
Figure 32: North America Drug Discovery Informatics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 33: Europe Drug Discovery Informatics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 34: Europe Drug Discovery Informatics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 35: Europe Drug Discovery Informatics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 36: Europe Drug Discovery Informatics Market Value Share Analysis, by Product, 2022 and 2031
Figure 37: Europe Drug Discovery Informatics Market Value Share Analysis, by Mode, 2022 and 2031
Figure 38: Europe Drug Discovery Informatics Market Value Share Analysis, by Function, 2022 and 2031
Figure 39: Europe Drug Discovery Informatics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 40: Europe Drug Discovery Informatics Market Attractiveness Analysis, by Product, 2023–2031
Figure 41: Europe Drug Discovery Informatics Market Attractiveness Analysis, by Mode, 2023–2031
Figure 42: Europe Drug Discovery Informatics Market Attractiveness Analysis, by Function, 2023–2031
Figure 43: Europe Drug Discovery Informatics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 44: Asia Pacific Drug Discovery Informatics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2023–2031
Figure 45: Asia Pacific Drug Discovery Informatics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Asia Pacific Drug Discovery Informatics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 47: Asia Pacific Drug Discovery Informatics Market Value Share Analysis, by Product, 2022 and 2031
Figure 48: Asia Pacific Drug Discovery Informatics Market Value Share Analysis, by Mode, 2022 and 2031
Figure 49: Asia Pacific Drug Discovery Informatics Market Value Share Analysis, by Function, 2022 and 2031
Figure 50: Asia Pacific Drug Discovery Informatics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Asia Pacific Drug Discovery Informatics Market Attractiveness Analysis, by Product, 2017–2031
Figure 52: Asia Pacific Drug Discovery Informatics Market Attractiveness Analysis, by Mode, 2023–2031
Figure 53: Asia Pacific Drug Discovery Informatics Market Attractiveness Analysis, by Function, 2023–2031
Figure 54: Asia Pacific Drug Discovery Informatics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 55: Latin America Drug Discovery Informatics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 56: Latin America Drug Discovery Informatics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 57: Latin America Drug Discovery Informatics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 58: Latin America Drug Discovery Informatics Market Value Share Analysis, by Product, 2022 and 2031
Figure 59: Latin America Drug Discovery Informatics Market Value Share Analysis, by Mode, 2022 and 2031
Figure 60: Latin America Drug Discovery Informatics Market Value Share Analysis, by Function, 2022 and 2031
Figure 61: Latin America Drug Discovery Informatics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 62: Latin America Drug Discovery Informatics Market Attractiveness Analysis, by Product, 2023–2031
Figure 63: Latin America Drug Discovery Informatics Market Attractiveness Analysis, by Mode, 2023–2031
Figure 64: Latin America Drug Discovery Informatics Market Attractiveness Analysis, by Function, 2023–2031
Figure 65: Latin America Drug Discovery Informatics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 66: Middle East & Africa Drug Discovery Informatics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 67: Middle East & Africa Drug Discovery Informatics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 68: Middle East & Africa Drug Discovery Informatics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 69: Middle East & Africa Drug Discovery Informatics Market Value Share Analysis, by Product, 2022 and 2031
Figure 70: Middle East & Africa Drug Discovery Informatics Market Value Share Analysis, by Mode, 2022 and 2031
Figure 71: Middle East & Africa Drug Discovery Informatics Market Value Share Analysis, by Function, 2022 and 2031
Figure 72: Middle East & Africa Drug Discovery Informatics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 73: Middle East & Africa Drug Discovery Informatics Market Attractiveness Analysis, by Product, 2023–2031
Figure 74: Middle East & Africa Drug Discovery Informatics Market Attractiveness Analysis, by Mode, 2023–2031
Figure 75: Middle East & Africa Drug Discovery Informatics Market Attractiveness Analysis, by Function, 2023–2031
Figure 76: Middle East & Africa Drug Discovery Informatics Market Attractiveness Analysis, by End-user, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Drug Discovery Informatics Market
*86 figures and 60 tables includes